What is Hummingbird?
Hummingbird, developed by Preceptis Medical, is a specialized medical device platform centered on the Hummingbird Tympanostomy Tube System (TTS). The technology is engineered to facilitate pediatric ear tube placements in an office setting, effectively eliminating the necessity for general anesthesia. This shift in clinical practice addresses a significant pain point in pediatric healthcare, where recurrent ear infections often necessitate invasive, high-cost surgical procedures. By streamlining the delivery of care, Hummingbird offers a value proposition that reduces procedural costs by up to 65% while enhancing the patient experience. The company operates at the intersection of medical device innovation and healthcare cost optimization, targeting a high-volume market segment that demands safer, more accessible alternatives to conventional operating room procedures.
How much funding has Hummingbird raised?
Hummingbird has raised a total of $5.4M across 3 funding rounds:
Series A
$4.4M
Debt
$976K
Debt
$83K
Series A (2014): $4.4M, investors not publicly disclosed
Debt (2015): $976K, investors not publicly disclosed
Debt (2021): $83K supported by PPP
Key Investors in Hummingbird
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Hummingbird?
With the recent infusion of capital, Hummingbird is poised to scale its commercial footprint and deepen its penetration into the pediatric ENT market. The strategic focus will likely shift toward expanding provider training programs and securing broader insurance reimbursement pathways to solidify its market position. As the company transitions from its initial development phase into a mature growth stage, the emphasis will remain on demonstrating long-term clinical efficacy and cost-saving metrics to hospital systems and private practices alike. Future growth will be predicated on the ability to maintain high adoption rates among surgeons who are increasingly incentivized to move procedures out of the hospital environment to improve operational margins and patient outcomes.
See full Hummingbird company page
